Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05123482 · ClinicalTrials.gov registry record · Phase 1
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
A Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 460
- Enrollment target
- 20
- Study locations
NCT05123482: Recruiting Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by AstraZeneca.
NCT05123482 is a Phase 1 study of Breast Cancer and Ovarian Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 460 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05123482, a Phase 1 study of Breast Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 460 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Primary Outcome
Number of patients with adverse events by system organ class and preferred term
Conditions Studied
Interventions
- DRUG AZD8205
- DRUG AZD8205 and AZD2936 (Rilvegostomig)
- DRUG AZD8205 and AZD5305 (saruparib)
- DRUG AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
- DRUG AZD8205 in combination with AZD9574
Study Locations (20)
Other
- Research Site - Clayton
- Research Site - Melbourne
- Research Site - Nedlands
- Research Site - Anderlecht
- Research Site - Leuven
California
- Research Site - Duarte
- Research Site - Irvine
- Research Site - Santa Monica
- Research Site - Santa Rosa
New York
- Research Site - Commack
- Research Site - New York
Louisiana
- Research Site - Shreveport
Maryland
- Research Site - Baltimore
Massachusetts
- Research Site - Boston
Missouri
- Research Site - St Louis
New Mexico
- Research Site - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2027-09-29 |
| Phase | Phase 1 |
What NCT05123482 shows while recruiting
NCT05123482 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which AZD8205 is the first listed.
NCT05123482 names 20 study sites across 12 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT05123482 about?
NCT05123482 is a clinical study titled "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies". This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
What is the current status of trial NCT05123482?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 460 participants. The study started on 2021-10-18. Estimated completion is 2027-09-29.
What conditions does trial NCT05123482 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer, Biliary Tract Carcinoma.
What interventions are being tested in trial NCT05123482?
The interventions under investigation include: AZD8205 (DRUG), AZD8205 and AZD2936 (Rilvegostomig) (DRUG), AZD8205 and AZD5305 (saruparib) (DRUG), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) (DRUG), AZD8205 in combination with AZD9574 (DRUG).
Who is sponsoring clinical trial NCT05123482?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05123482 being conducted?
This trial has 20 study locations across California, Louisiana, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05123482's enrollment target sits among peer trials
460 212th of 1224 higher than 1,013 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI